Please help with calculating rate ratio

Statins are a class of drugs that have been demonstrated to be effective in lowering blood levels of cholesterol and significantly reducing the incidence of major cardiac events (heart attack, stroke, severe angina) in patients with elevated cholesterol levels. However, certain groups of people who do not have elevated cholesterol levels are still at increased risk of having a major cardiac event, including people who have elevations in an inflammatory marker called C-reactive protein. In Nov. 2008 the New England Journal of Medicine published the results of a study in which the investigators enrolled 17,802 subjects who had no history of heart disease. All subjects had elevated levels of C-reactive protein, but they all had normal cholesterol levels. Subjects were randomly assigned to receive either the statin Rosuvastatin (Crestor) 20 mg. per day or a placebo that looked identical to the active agent. The drugs were coded, and neither the investigators nor the subjects know who was receiving the active drug. Subjects were followed for an average duration of about two years. Several points from the Methods section of the paper. "Follow-up visits were scheduled to occur at 13 weeks and then 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after randomization. Follow-up assessments included laboratory evaluations, pill counts, and structured interviews assessing outcomes and potential adverse events." "The primary outcome was the occurrence of a first major cardiovascular event, defined as nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, an arterial revascularization procedure, or confirmed death from cardiovascular causes." "All reported primary end points that occurred through March 30, 2008, were adjudicated on the basis of standardized criteria by an independent end-point committee unaware of the randomized treatment assignments. Only deaths classified as clearly due to cardiovascular or cerebrovascular causes by the end- point committee were included in the analysis of the primary end point." The following table summarizes the main findings of the study. Group Subjects Major Cardiac Events Person-years Crestor (statin) 8,901 142 18,442 Placebo 8,901 251 18,529 Using the data from the table above, calculate the rate ratio for the overall effect of Crestor compared to placebo. Round your answer to two decimal places (e.g., if your answer is 1.2345, the rounded answer would be 1.23; if your answer is 1.2365, the rounded answer would be 1.24), and submit your numeric